Author

Daniele Parisi

KU LeuvenORCID 0000-0002-2497-7487Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Daniele Parisi1 paper · Scripps Research Institute

Biology Disciplines

Click to filter author papers

Bioinformatics· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:benchmarking· 1 Research Focus:database / resource· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:protein structure· 1 Research Focus:software / tool· 1 Approach:statistical model· 1

Frequent Co-Authors

Melissa F. AdasmeiD· 2 shared Michael SchroederiD· 2 shared Yves MoreauiD· 2 shared Anastasia N. SveshnikovaiD· 1 shared Ben SprangersiD· 1 shared Gary S. Jennings· 1 shared Jean HermaniD· 1 shared Jörg C. Heinrich· 1 shared

Activity by Year

2020-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioinformatics

Melissa F. AdasmeORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Structure-based drug repositioning explains ibrutinib as VEGFR2 inhibitor

Melissa F. Adasme, Daniele Parisi, Kristien Van Belle, Sebastian Salentin, V. Joachim Haupt, Gary S. Jennings, Jörg C. Heinrich, Jean Herman, Ben Sprangers, Thierry Louat, Yves Moreau, Michael Schroeder

This paper identifies ibrutinib as a VEGFR2 inhibitor through structure-based drug repositioning, revealing its polypharmacological action beyond BTK.

PLoS ONE · May 27, 2020Peer-reviewedBioinformatics

Drug repositoning or target repositioning: a structural perspective of drug-target-indication relationship for available repurposed drugs.

Daniele Parisi, Melissa F. Adasme, Anastasia N. Sveshnikova, Sarah Naomi Bolz, Yves Moreau, Michael Schroeder

The paper evaluates drug repositioning approaches by analyzing 100 drugs, 200 targets, and 300 indications, finding that disease and target-centric methods dominate over drug-centric ones.

Computational and Structural Biotechnology Journal · Jan 1, 2020Peer-reviewedBioinformatics